The processes required for C> manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.
Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.
Read the full report
Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:
Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.
To find out more about our capabilities, contact:
020 3910 8000
+1 646 503 3048
+852 3974 8841
The Relevance of Silver in a Global Multi-Asset Portfolio
This study examines whether silver should be viewed as a distinct asset class that warrants a strategic investment allocation within an efficient multi-asset portfolio.Find Out More
Achieving data-led innovation for the modern supply chain
A persistent pandemic, economic uncertainty, and a global geopolitical conflict continue to dominate headlines and fuel Chief Supply Chain Officer (CSCO) frustrations. Navigating uncertainties—and managing supply chain challenges accordingly—has out of necessity become a top business priority for boards and C-suites alike.Find Out More
The Economic Impact of Drax Group in the U.K., U.S. and Canada
This study investigates Drax Group’s economic impact in the U.K., U.S., and Canada. It considers Drax’s own operations, the economic activity supported by its procurement spending and the impact of the wage payments to employees. We also consider the social value delivered by Drax Group.Find Out More